Vol. 19, Bulletin No. 108 August-September 2012 Also in the Bulletin: Denosumab 120mg for Bone Metastases
|
|
- Asher Jessie Gilbert
- 5 years ago
- Views:
Transcription
1 ה מ ר א פ הביטאון לענייני תרופות ISRAEL DRUG BULLETIN 19 years of unbiased and independent drug information P H A R x M A Vol. 19, Bulletin No. 108 August-September 2012 Also in the Bulletin: Denosumab 120mg for Bone Metastases DENOSUMAB 60mg FOR FRACTURE PREVENTION When injected every 6 months, denosumab, a monoclonal antibody that decreases bone resorption, appeared to reduce fractures in women with postmenopausal osteoporosis in a large placebo-controlled trial. In a placebo-controlled trial with castrated men with prostate cancer, denosumab did not significantly reduce the incidence of symptomatic fractures after 3 years; the incidence of new radiological vertebral fractures did show a significant decline. The effect of denosumab on fracture rates compared with that of other antiresorptive therapies is not known. Patients may prefer the 6-monthly dosing of denosumab but will need to consider its increased risks of infections and malignancies. Denosumab can lower serum calcium concentrations, especially in patients with impaired renal function Due to the lack of long-term safety data, denosumab should be reserved only for patients with osteoporosis or low bone mineral density at risk of osteoporotic fractures for whom use of established treatments to prevent osteoporotic fractures is not possible or contraindicated. Osteoporosis occurs when bone resorption (osteoclast activity) exceeds bone formation (osteoblast activity). Osteoporosis is defined as low bone mass and microarchitectural deterioration of bone tissue, resulting in bone fragility and an increased risk of fracture. The clinically apparent and relevant outcome of osteoporosis is a fragility fracture, which usually occurs in the vertebrae, hip or wrist. The efficacy of bisphosphonates and other drugs in the reduction of fractures remain quite uncertain. In postmenopausal women with severe osteoporosis (low BMD with history of fracture after mild trauma) the standard drug is alendronic acid, despite its modest efficacy. There is inadequate evidence to support the use of drugs to treat osteoporosis in men. There are no drugs with demonstrated efficacy in the reduction in the incidence of fractures in men with bone loss due to hormonal treatment for prostate cancer. Denosumab, a monoclonal antibody that decreases bone resorption, is the first in a new class of drugs to treat osteoporosis. Denosumab 60mg (Prolia; Amgen), given subcutaneously every 6 months, is approved in Israel for the treatment of osteoporosis in fracture prevention in postmenopausal women at increased risk of fractures; for the treatment of bone loss associated with hormone ablation in men with prostate cancer at increased risk of fracture. Denosumab is the first licensed product to treat osteoporosis in men having androgen-deprivation therapy. Denosumab has also been approved with a different dosage (120mg) and brand name (Xgeva) for prevention of skeletal-related events in adults with bone metastases from solid tumours. An assessment of evidence for this indication is covered in the next article. MODE OF ACTION Denosumab is a human monoclonal antibody that inhibits a cytokine called RANKL (Receptor Activity of Nuclear factor-kappa B Ligand). RANKL binding to the RANK receptor on the surface of osteoclasts stimulates the formation, activity and survival of osteoclasts, 1 thereby increasing resorption of cortical and trabecular bone. Thus denosumab inhibits the development and activity of osteoclasts and leads to decreased bone resorption and increased bone modelling. RANKL also stimulates B and T cell differentiation and maturation. Following a subcutaneous dose of denosumab 60mg, maximum serum concentrations are typically reached 1-4 weeks later and remain high enough to inhibit bone turnover for at least 6 months. By 9 months they fall below the effective range. Denosumab has an elimination halflife of 26 days. It is not eliminated via hepatic metabolism 1
2 and dose adjustment is not needed in patients with renal impairment. CLINICAL STUDIES Clinical evaluation of denosumab with clinical fracture prevention as an endpoint consists only of a single placebo-controlled trial in each of its indications. There are no published trials comparing denosumab with alendronate or other bisphosphonates in terms of fracture. Nor are there such studies on the efficacy in women who do not respond to bisphosphonates. No active comparator could be used in the study in men as there is no therapy currently licensed for the treatment of osteoporosis in men having androgen-deprivation therapy. EFFICACY IN OSTEOPOROSIS IN POSTMENO- PAUSAL WOMEN The approval of denosumab for osteoporosis is mainly based on a large randomised placebo-controlled trial 2 which enrolled 7,868 women aged years (T-scores between -2.5 and -4); in about one quarter of women there was a history of vertebral fracture. Primary endpoint included morphometric fractures which can only be diagnosed radiographically. Denosumab 60mg injected SC every 6 months for 3 years reduced the incidence of vertebral fractures compared to placebo from 7.2% to 2.3%; symptomatic vertebral fractures from 2.6% to 0.8%; hip fracture from 1.2% to 0.7%, and nonvertebral fracture from 8.0% to 6.5%, all statistically significant differences. Bone formation returns to base levels within 1 year after the cessation of denosumab therapy. Although the efficacy data from this trial looks promising, a meta-analysis of three randomised controlled trials found that denosumab was not associated with a significant reduction in fracture risk in postmenopausal women. 3 The lack of trials directly comparing the efficacy of denosumab and alendronate at 3 years justifies an indirect comparison, even though the results provide only weak evidence. On this basis, denosumab does not appear to be superior to alendronate: among 100 women treated for 3 years, respectively 1.8 and 3.0 symptomatic vertebral fractures would be prevented, while 0.5 versus 1.0 hip fractures would be prevented. 4 Effect on BMD and Bone Markers vs Alendronate In a 12-month study in women with low bone mass (Tscore <-2), denosumab 60mg injected SC every 6 months increased bone mineral density (primary endpoint) measured at various skeletal sites, more than 70mg alendronate (3.5% vs 2.6%) taken once weekly. 5 Although this was statistically significant, the clinical significance of this change is unclear. This increase was associated with a more pronounced decrease in markers for bone turnover in the denosumab group. In another study, 504 women with osteoporosis (BMD T-score below -2.0) who had taken alendronate for at least 6 months, switching to denosumab for an additional 12 months was more effective in increasing BMD in total hip, lumbar spine, femoral neck, and 1/3 radius than continuing on alendronate. 6 Patients enrolled were not necessarily intolerant to bisphosphonates or experienced further decline while taking bisphosphonates, limiting the applicability of the results. There was a similar incidence in both treatment groups with regard to adverse events and serious adverse events. In both these studies, 5,6 the incidence of fracture rates were higher in the denosumab treated patients compared to the alendronate-treated patients. However, neither of these studies was powered to compare the fracture rates. EFFICACY IN OSTEOPOROSIS IN CASTRATED MEN WITH PROSTATE CANCER Men (n=1468) with prostate cancer receiving androgen-deprivation therapy with a BMD T-score below - 1 (lumbar spine, total hip or femoral neck) were randomised to treatment with either denosumab 60mg every 6 months or placebo for 3 years. 7 About 20% of the men had a history of vertebral fractures. The primary endpoint was the change in BMD from baseline of the lumbar spine at 24 months: +5.6% in the denosumab group vs -1.0% in the placebo group (p<0.001). Secondary endpoints were the changes in BMD at the total hip, femoral neck, distal third of radius and whole body, p<0.001 for all, in favour of denosumab. Fractures at any site were more prevalent in the placebo group at 36 months (7.2% vs 5.2%) but this was not statistically significant. A higher rate of vertebral fractures occurred in the placebo group compared with the denosumab group at 24 months (3.3% vs 1.0%, p=0.004) and at 36 months (3.9% vs. 1.5%, p=0.006). The incidence of vertebral fractures detected by routine radiography was lower with denosumab (1.5% vs 3.5%, p=0.0125), but the available reports do not indicate whether this translated into a lower incidence of symptomatic fractures. ADVERSE EFFECTS As RANKL is expressed on immune cells denosumab may result in immunosuppression potentially increasing the incidence of cancer and infection. Denosumab is a monoclonal antibody and thus carries a risk of immune reaction although neutralizing antibodies were not found in women taking denosumab. None of the trials saw an increase in the rate of serious infections or neoplasms, though an increased rate of cellulitis and eczema was reported. 1 When a larger safety cohort (over 8000 patients) was analysed, serious infections were more common with denosumab than placebo (3.4% vs 2.8%) and included abdominal, ear and urinary tract infections as well as cellulitis. Endocarditis, 2
3 septic arthritis and skin ulcers were also more frequently reported. Cancers were slightly more common with denosumab than with placebo (7.8% vs 7.1%). These risks should be considered when prescribing denosumab and patients should be informed of them. In the safety cohort, serious pancreatitits occurred more commonly with denosumab than with placebo (9 cases vs 1 case). 4,8 Osteoporosis of the jaw has been reported. Low osteoclast and osteoblast counts have been observed with denosumab. 1 Whether long-term suppression of bone remodeling with denosumab creates a risk of atypical fractures and delayed fracture healing is unknown. Denosumab can lower serum calcium concentrations, especially in patients with impaired renal function; it is contraindicated for use in patients with hypocalcaemia. Calcium and vitamin D supplementation is recommended for all patients. Drug interactions: No studies have been carried out. DOSAGE AND COSTS Anti-Resorptive Therapies: Fracture Prevention Drug Denosumab (Prolia) Annual Cost (NIS)* Dose 60mg SC injection every 6 months 2,658 Alendronic acid (generic) 70mg weekly 1,000 Raloxifene (Evista) 60mg daily 2,993 Risedronate (generic) 35mg weekly 1,304 Strontium ranelate (Protelos) 2gm daily 3,110 Teriperatide (Forteo) 20mcg SC injection daily** 36,396*** Zoledronic acid (Aclasta) 5mg IV infusion yearly 2,347 *based on maximum retail price approved by the MoH. **maximum duration of treatment 18 months; course not to be repeated. **based on 28 doses per 3ml vial. CONCLUSIONS In a placebo-controlled trial denosumab taken for three years was seen to have a modest protective effect on fractures in postmenopausal women with low BMD. The primary endpoint included morphometric fractures which can only be diagnosed radiographically and in practice would not normally be diagnosed and treated. Because there is a lack of head-to-head trials, it is not known how denosumab compares with other treatments for osteoporosis; it appears to be more effective than weekly alendronate in increasing BMD (a surrogate measure). In men receiving androgen-deprivation therapy for prostate cancer, a placebo-controlled trial did not show that denosumab had a significant protective effect in reducing fractures. Clinical trials of denosumab raised significant safety issues; patients will need to consider denosumab's increased risk of infections and malignancies. Long-term data on safety and efficacy are needed. Denosumab may be an option for women with osteoporosis or low BMD at risk of osteoporotic fractures for whom use of established treatments to prevent osteoporotic fractures is not possible or contraindicated. However, studies on the efficacy in women who do not respond to bisphosphonates are lacking. References 1. Lipton A & Goessi C, Bone 48:96, Cummings S et al, N Engl J Med 361:756, Anastasilakis A et al, Horm Metab Res 41:721, Prescrire Int 20:145, Brown J et al, J Bone Miner Res 24:153, Kendler D et al, J Bone Miner Res 25:72, Smith M et al, N Engl J Med 361:745, Australian Prescriber 33:194, DENOSUMAB 120mg for TREATMENT of BONE METASTASES Denosumab, a monoclonal antibody that decreases bone resorption, has been approved at a 120mg dose every 4 weeks for prevention of skeletal-related events in adults with bone metastases from solid tumours. Denosumab 120mg subcutaneous was compared with IV zoledronic acid in patients with breast cancer, with prostate cancer, and with advanced cancers or multiple myeloma. Time to first skeletal-related event was delayed by denosumab by about 17% in all three cancer groups. Data for outcomes such as pain, survival and quality of life did not show consistent benefit over zoledronic acid. The use of denosumab 120mg every 4 weeks in patients with severe renal impairment and its efficacy following IV bisphosphonate therapy were not assessed. Adverse events occurred to a similar extent with denosumab 120mg and zoledronic acid, including osteonecrosis of the jaw. Adverse renal effects occurred to a higher degree in breast cancer studies with zoledronic acid, but to a similar extent in the other two studies. Denosumab carries the risk of hypocalcaemia. About 70% of patients with metastatic breast cancer and prostate cancer develop bone metastases. The risk of developing a pathological fracture in a patient with metastatic bone disease is nearly 4 times more likely over 3
4 a 5-year period than in a patient without metastatic bone disease. 1 Bisphosphonates are currently used to treat such patients: sodium pamidronate and zoledronic acid are given by IV infusion (every 4 weeks) and sodium clodronate is an oral therapy taken daily. The Israel MoH has approved denosumab 120mg (Xgeva; Amgen) for the prevention of skeletal-related events (pathological fracture, radiation to bone, spinal cord compression or surgery to bone) in adults with bone metastases from solid tumours. Denosumab 60mg (Prolia) is also licensed for the treatment of osteoporosis in postmenopausal women at risk of fracture, and for bone loss in men having hormonal ablation for prostate cancer who are at risk of fracture. Denosumab is a monoclonal antibody that decreases bone resorption; details of its mode of action can be found in the previous article. CLINICAL STUDIES Denosumab has been compared in three double-blind studies with zoledronic acid for treating bone metastases in patients with advanced breast cancer, 2 castrationresistant prostate cancer 3 and advanced cancer (excluding breast and prostate) or multiple myeloma. 4 All three studies had the same design: patients were randomised to either denosumab 120mg by SC injection or zoledronic acid 4mg by IV infusion (dose adjusted to renal function), every 4 weeks, plus matching placebo. The primary endpoint was time to first on-study skeletal related event (SRE) (non-inferiority). SRE were defined as pathologic fracture (assessed by X-rays every 12 weeks or radiographic assessments during the course of standard care), radiation therapy or surgery to bone or spinal cord compression. The secondary endpoints were time to first SRE (superiority test, only carried out if noninferiority proven) and time to first and subsequent SRE. In clinical practice, assessment of fractures by skeletal surveys (X-rays) every 12 weeks may not take place. Breast cancer: 2 The time to first SRE was significantly delayed with denosumab vs zoledronic acid (32.4 months vs 27.4 months; p=0.01 for superiority). The proportion of patients with multiple SREs at the time of the extended analysis was 38.9% in the zoledronic acid group vs 32.9% in the denosumab group. The mean skeletal morbidity rate was significantly reduced with denosumab vs zoledronic acid, with significant difference in event rates (0.45 vs 0.58 events per patients per year, respectively, p=0.004). Prostate cancer: 3 The time to first SRE was significantly reduced by 3.6 months with denosumab (20.7 vs 17.1 months, p=0.008 for superiority). First study events occurred in 341 (36%) treated with denosumab and 386 (40.8%) treated with zoledronic acid. Advanced cancer: 4 The time to first SRE was significantly reduced by 6 months with denosumab treatment (21.4 vs 15.4 months, p=0.034 for superiority). The time to first and subsequent SREs was significantly reduced with denosumab (HR 0.85, p=0.048), with a cumulative mean number of SREs of 374 in patients treated with zoledronic acid and 328 in those treated with denosumab. Denosumab delayed the development of moderate to severe pain in patients with no or mild pain and delayed pain worsening compared with zoledronic acid. Overall survival and disease progression were similar between the treatment arms in all three studies. However, in multiple myeloma the rates of overall survival and disease progression were worse in patients treated with denosumab. Denosumab is not approved for nonsolid tumours. Integrated Analysis Integrated analysis of the primary and secondary endpoints from the above studies was carried out stratified by study and by factors within each study. 5 A total of 2988 SREs occurred, 1360 in the denosumab arm (n=2862) and 1628 in the zoledronic acid arm (n=2861). Time to first SRE was delayed by 17% with denosumab treatment, with median time to first SRE of 27.7 months with denosumab and 19.5 months with zoledronic acid (p<0.0001, for both non-inferiority and superiority endpoints). Time to clinically significant pain worsening (>-2-point increase from baseline) was delayed 6 with denosumab compared with zoledronic acid: 181 days vs. 169 days (p=0.026). In patients with no or with mild pain at baseline, the time to moderate/severe pain was 198 days with denosumab vs 143 days with zoledronic acid (p=0.002). Fewer patients with no or mild pain at baseline who were treated with denosumab reported moderate or severe pain, compared with those treated with zoledronic acid. This was statistically significant from week 13 onwards (p<0.05). ADVERSE EFFECTS Fatigue, dyspnoea, diarrhoea and nausea are commonly reported adverse effects. Denosumab can lower serum calcium concentrations, especially in patients with impaired renal function. It should not be used in patients with severe, untreated hypocalcaemia. Denosumab had a lower incidence of acute phase reactions (occurring in the first 3 days post-administration) than zoledronic acid (8.7% vs 20.2%). 5 Adverse renal effects occurred to a higher degree with zoledronic acid than with denosumab the breast cancer study (8.5% vs 4.9%), p=0.001), 2 but to a similar extent between the treatment arms in the other two studies. 3,4 Osteonecrosis of the jaw occurred in both treatment arms and most were associated with known risks such as tooth extractions or poor dental health. In the integrated analysis, the incidence was 1.8% in the denosumab arm and 1.3% in the zoledronic arm (p=0.13). 5 4
5 DOSAGE AND COSTS Anti-Resorptive Therapies: Bone Metastases Monthly Cost Drug Dose (NIS)* Denosumab (Xgeva) 120mg SC injection every 4 weeks 2,465 Disodium pamidronate (Aredia) 90mg IV infusion every 4 weeks 826 Zoledronic acid (Zomera) 4mg IV infusion every 4 weeks 1,795 *based on maximum retail price approved by the MoH. CONCLUSIONS The evidence directly comparing denosumab with zoledronic acid suggests that denosumab is more clinically effective in preventing skeletal-related events than zoledronic acid in the three cancer groups for which there were trial evidence. However, data for other outcomes such as pain, quality of life and survival did not show a consistent benefit over zoledronic acid. The optimal duration of denosumab treatment is unknown. Although denosumab may be given without the need for renal monitoring unlike zoledronic acid, it carries the risk of hypocalcaemia. Hypocalcaemia should be corrected prior to treatment with denosumab. The use of denosumab 120mg every 4 weeks in patients with severe renal impairment was not assessed. There may be some patients who could benefit from the administration of denosumab 120mg, such as those who do not respond adequately to bisphosphonates; those who are intolerant or contraindicated to bisphosphonates; those at risk of or have renal dysfunction and those with poor intravenous access. The efficacy of denosumab following IV bisphosphonate therapy was not assessed. There would be little point in administering denosumab and bisphosphonates together: denosumab suppresses bone turnover to a greater extent than IV bisphosphonates, so concurrent bisphosphonate treatment would not be expected to result in significant further suppression of bone resorption nor added clinical efficacy. The adverse effects of bisphosphonate treatment would still be expected. (Denosumab was also assessed in a double-blind placebo-controlled trial for prevention of bone metastases or death in non-metastatic castration-resistant prostate cancer patients at high risk of bone metastasis. 7 The findings do not support the non-approved use of denosumab 120mg as a preventive agent for bone metastases in prostate cancer.) References 1. Bottiglieri S and Adams V, Orthopedics 33:557, Stopeck A et al, J Clin Oncol 28:5132, Fizazi K et al, Lancet 377:813, Henry D et al, J Clin Oncol 29, 1125, Lipton A et al, Ann Oncol 21:viii:380 (abstract 1249P), Cleeland C et al, Ann Oncol 21:viii:380 (abstract 1248P), Smith M et al, Lancet 379:39, Although great care has been taken in compiling the contents of this publication, the publisher and the editor are not responsible or in any way liable for the accuracy of the information, for any errors, omissions or inaccuracies, or from any consequences therefrom. Inclusion or exclusion of any product does not imply its use is either advocated or rejected. Opinions expressed do not necessarily reflect the views of the publisher or editor. In addition to the information supplied herein, reference should always be made to the manufacturer s literature in respect of each drug before it is prescribed. PHARMA Drug Bulletin is a Member of the International Society of Drug Bulletins 5
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 11 April 2012
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 11 April 2012 XGEVA 120 mg, solution for injection 1 glass vial of 120 mg/1.7 ml (CIP code: 217 253-8) 4 glass vials
More informationDENOSUMAB (PROLIA & XGEVA )
DENOSUMAB (PROLIA & XGEVA ) UnitedHealthcare Oxford Clinical Policy Policy Number: PHARMACY 306.3 T2 Effective Date: July 2, 2018 Table of Contents Page INSTRUCTIONS FOR USE... 1 CONDITIONS OF COVERAGE...
More informationPresenter: 翁家嫻 Venue date:
FOR THE TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN AT INCREASED RISK OF FRACTURES 1 Presenter: 翁家嫻 Venue date: 2018.03.13 PMO: postmenopausal osteoporosis. 1. Prolia (denosumab), Summary of Product
More informationOsteoporosis update. Dr. Claire Vandevelde Consultant Rheumatologist, LTHT
Osteoporosis update Dr. Claire Vandevelde Consultant Rheumatologist, LTHT Outline Background BMD Tools for assessing fracture risk Case study Denosumab Treatment breaks BMD BMD predicts fracture risk but
More informationHorizon Scanning Technology Briefing. Zoledronic Acid (Aclasta) once yearly treatment for postmenopausal. National Horizon Scanning Centre
Horizon Scanning Technology Briefing National Horizon Scanning Centre Zoledronic Acid (Aclasta) once yearly treatment for postmenopausal osteoporosis December 2006 This technology summary is based on information
More informationHorizon Scanning Centre March Denosumab for glucocorticoidinduced SUMMARY NIHR HSC ID: 6329
Horizon Scanning Centre March 2014 Denosumab for glucocorticoidinduced osteoporosis SUMMARY NIHR HSC ID: 6329 This briefing is based on information available at the time of research and a limited literature
More informationDenosumab (AMG 162) for bone metastases from solid tumours and multiple myeloma
Denosumab (AMG 162) for bone metastases from solid tumours and multiple myeloma September 2008 This technology summary is based on information available at the time of research and a limited literature
More informationUpdates in Osteoporosis. I have no conflicts of interest. What Would You Do? Mrs. C. What s New in Osteoporosis. Page 1
Updates in Osteoporosis Jeffrey A. Tice, MD Associate Professor of Medicine Division of General Internal Medicine, University of California, San Francisco I have no conflicts of interest What s New in
More informationBased on review of available data, the Company may consider the use of denosumab (Prolia) for the
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
More informationdenosumab (Prolia ) Policy # Original Effective Date: 07/21/2011 Current Effective Date: 04/19/2017
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
More informationXgeva. Xgeva (denosumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.30.18 Subject: Xgeva Page: 1 of 5 Last Review Date: March 16, 2018 Xgeva Description Xgeva (denosumab)
More informationXgeva. Xgeva (denosumab) Description. Section: Prescription Drugs Effective Date: January 1, 2016
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.07.18 Subject: Xgeva Page: 1 of 5 Last Review Date: December 3, 2015 Xgeva Description Xgeva (denosumab)
More informationPharmacy Management Drug Policy
Clinical criteria used to make utilization review decisions are based on credible scientific evidence published in peer reviewed medical literature generally recognized by the medical community. Guidelines
More informationPharmacy Management Drug Policy
SUBJECT: - Forteo (teriparatide), Prolia (denosumab), Tymlos (abaloparatide) POLICY NUMBER: Pharmacy-35 EFFECTIVE DATE: 9/07 LAST REVIEW DATE: 9/29/2017 If the member s subscriber contract excludes coverage
More informationWhat is Osteoporosis?
What is Osteoporosis? 2000 NIH Definition A skeletal disorder characterized by compromised bone strength predisposing a person to an increased risk of fracture. Bone strength reflects the integration of
More informationOsteoporosis Update. Greg Summers Consultant Rheumatologist
Osteoporosis Update Greg Summers Consultant Rheumatologist DEFINITION OSTEOPOROSIS is LOW BONE MASS (& micro-architectural deterioration) causing AN INCREASED RISK OF FRACTURE 23 years 82 years 23 y/o
More informationForteo (teriparatide) Prior Authorization Program Summary
Forteo (teriparatide) Prior Authorization Program Summary FDA APPROVED INDICATIONS DOSAGE 1 FDA Indication 1 : Forteo (teriparatide) is indicated for: the treatment of postmenopausal women with osteoporosis
More informationOsteoporosis Agents Drug Class Prior Authorization Protocol
Osteoporosis Agents Drug Class Prior Authorization Protocol Line of Business: Medicaid P&T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed through review of
More informationPharmacy Management Drug Policy
SUBJECT: - Forteo (teriparatide), Prolia (denosumab), Tymlos (abaloparatide), Boniva injection (Ibandronate) POLICY NUMBER: Pharmacy-35 EFFECTIVE DATE: 9/07 LAST REVIEW DATE: 10/15/2018 If the member s
More informationBone Metastases. Sukanda Denjanta, M.Sc., BCOP Pharmacy Department, Chiangrai Prachanukroh Hospital
Bone Metastases Sukanda Denjanta, M.Sc., BCOP Pharmacy Department, Chiangrai Prachanukroh Hospital 1 Outline Pathophysiology Signs & Symptoms Diagnosis Treatment Spinal Cord Compression 2 General Information
More informationS H A R E D C A R E G U I D E L I N E Drug: Denosumab 60mg injection Indication: treatment of osteoporosis in postmenopausal women
S H A R E D C A R E G U I D E L I N E Drug: Denosumab 60mg injection Indication: treatment of osteoporosis in postmenopausal women Introduction Indication: Denosumab (Prolia ) is recommended in NICE TA204
More informationElderly men with prostate cancer + ADT
Elderly men with prostate cancer + ADT Background and Rationale ADT and Osteoporosis Proportion of Patients With Fractures 1-5 Yrs After Cancer Diagnosis 21 18 +6.8%; P
More informationScottish Medicines Consortium
Scottish Medicines Consortium zoledronic acid 5mg/100ml solution for infusion (Aclasta) No. (317/06) Novartis 8 September 2006 The Scottish Medicines Consortium (SMC) has completed its assessment of the
More informationAn Update on Osteoporosis Treatments
An Update on Osteoporosis Treatments Dr Mike Stone University Hospital Llandough Treatments for osteoporosis Calcium and vitamin D HRT Raloxifene Etidronate Alendronate Risedronate Ibandronate (oral and
More informationParathyroid Hormone Analog for Osteoporosis Prior Authorization with Quantity Limit Criteria Program Summary
Parathyroid Hormone Analog for Osteoporosis Prior Authorization with Quantity Limit Criteria Program Summary This prior authorization program applies to Commercial, NetResults A series, NetResults F series
More informationBREAST CANCER AND BONE HEALTH
BREAST CANCER AND BONE HEALTH Rowena Ridout, MD, FRCPC Toronto Western Hospital Osteoporosis Program University Health Network / Mount Sinai Hospital rowena.ridout@uhn.ca None to declare Conflicts of Interest
More informationClinical Specialist Statement Template
Clinical Specialist Statement Template Thank you for agreeing to give us a statement on your organisation s view of the technology and the way it should be used in the NHS. Healthcare professionals can
More informationProduct: Denosumab (AMG 162) Abbreviated Clinical Study Report: (Extension Phase Results) Date: 24 August 2010 Page Page 2 of 2 of
Product: Denosumab (MG 162) bbreviated Clinical Study Report: 20040114 (Extension Phase Results) Date: 24 ugust 2010 Page Page 2 of 2 of 1314 55 2. SYNOPSIS Name of Sponsor: mgen Inc. Name of Finished
More informationUpdates in Osteoporosis
Updates in Osteoporosis Jeffrey A. Tice, MD Associate Professor of Medicine Division of General Internal Medicine, University of California, San Francisco I have no conflicts of interest What s New in
More informationAssessment and Treatment of Osteoporosis Professor T.Masud
Assessment and Treatment of Osteoporosis Professor T.Masud Nottingham University Hospitals NHS Trust University of Nottingham University of Derby University of Southern Denmark What is Osteoporosis? Osteoporosis
More informationGuidance for the administration of Denosumab (Prolia ) in Primary Care GENERAL INFORMATION should be recommended
Guidance for the administration of Denosumab (Prolia ) in Primary Care GENERAL INFORMATION Denosumab is suitable for patients with established osteoporosis for both primary and secondary fracture prevention
More informationDifferentiating Pharmacological Therapies for Osteoporosis
Differentiating Pharmacological Therapies for Osteoporosis Socrates E Papapoulos Department of Endocrinology & Metabolic Diseases Leiden University Medical Center The Netherlands Competing interests: consulting/speaking
More informationProduct: Denosumab (AMG 162) Clinical Study Report: month Primary Analysis Date: 21 November 2016 Page 1
Date: 21 November 2016 Page 1 2. SYNOPSIS Name of Sponsor: Amgen Inc., Thousand Oaks, CA, USA Name of Finished Product: Prolia Name of Active Ingredient: denosumab Title of Study: Randomized, Double-blind,
More informationOsteoporosis. Treatment of a Silently Developing Disease
Osteoporosis Treatment of a Silently Developing Disease Marc K. Drezner, MD Senior Associate Dean Emeritus Professor of Medicine Emeritus University of Wisconsin-Madison Auditorium The Forest at Duke October
More informationSaad et al [12] Metastatic CRPC. Bhoopalam et al [14] M0 PCa on ADT <1 yr vs >1 yr ADT
Evolution of Treatment Options for Patients with and Bone Metastases Trials of Treatments for Castration-Resistant Prostrate Cancer Mentioned in This Review Bisphosphonates (Zometa) 4 mg IV 8 mg IV ( to
More informationHOW I DO IT. Introduction. BARKIN J. How I Do It: Managing bone health in patients with prostate cancer. Can J Urol 2014;21(4):
HOW I DO IT How I Do It: Managing bone health in patients with prostate cancer Jack Barkin, MD Department of Surgery, University of Toronto, Humber River Hospital, Toronto, Ontario, Canada BARKIN J. How
More informationThe Bare Bones of Osteoporosis. Wendy Rosenthal, PharmD
The Bare Bones of Osteoporosis Wendy Rosenthal, PharmD Definition A systemic skeletal disease characterized by low bone mass and microarchitectural deterioration of bone tissue, with a consequent increase
More informationBisphosphonates in the Management of. Myeloma Bone Disease
Bisphosphonates in the Management of Myeloma Bone Disease James R. Berenson, MD Medical & Scientific Director Institute for Myeloma & Bone Cancer Research Los Angeles, CA Myeloma Bone Disease Myeloma cells
More information2017 Santa Fe Bone Symposium McClung
217 Santa Fe Bone Symposium Insights into the Use of Anti-remodeling and Anabolic Agents for Osteoporosis Developing a Long-term Management Plan Michael R., MD, FACP Oregon Osteoporosis Center Portland,
More informationNew Developments in Osteoporosis: Screening, Prevention and Treatment
Osteoporosis: Overview New Developments in Osteoporosis: Screening, Prevention and Treatment Judith Walsh, MD, MPH Departments of Medicine and Epidemiology and Biostatistics UCSF Definitions Risk factors
More informationBreast Cancer and Bone Loss. One in seven women will develop breast cancer during a lifetime
Breast Cancer and Bone Loss One in seven women will develop breast cancer during a lifetime Causes of Bone Loss in Breast Cancer Patients Aromatase inhibitors Bil Oophorectomy Hypogonadism Steroids Chemotherapy
More informationHARVARD PILGRIM HEALTH CARE RECOMMENDED MEDICATION REQUEST GUIDELINES
Generic Brand HICL GCN Exception/Other PROLIA, XGEVA 37012 If the caller wishes to initiate a request then a MRF must be completed. This drug requires a written request for prior authorization. All requests
More informationMedication Policy Manual. Topic: Prolia, denosumab Date of Origin: August 11, 2010
Independent licensees of the Blue Cross and Blue Shield Association Medication Policy Manual Policy No: dru223 Topic: Prolia, denosumab Date of Origin: August 11, 2010 Committee Approval Date: August 11,
More informationAdvanced medicine conference. Monday 20 Tuesday 21 June 2016
Advanced medicine conference Monday 20 Tuesday 21 June 2016 Osteoporosis: recent advances in risk assessment and management Juliet Compston Emeritus Professor of Bone Medicine Cambridge Biomedical Campus
More informationOsteoporosis. Overview
v2 Osteoporosis Overview Osteoporosis is defined as compromised bone strength that increases risk of fracture (NIH Consensus Conference, 2000). Bone strength is characterized by bone mineral density (BMD)
More information1
www.osteoporosis.ca 1 2 Overview of the Presentation Osteoporosis: An Overview Bone Basics Diagnosis of Osteoporosis Drug Therapies Risk Reduction Living with Osteoporosis 3 What is Osteoporosis? Osteoporosis:
More informationThank you for agreeing to give us a statement on your organisation s view of the technology and the way it should be used in the NHS.
Appendix I - Thank you for agreeing to give us a statement on your organisation s view of the technology and the way it should be used in the NHS. Healthcare professionals can provide a unique perspective
More informationOsteoporosis. When we talk about osteoporosis, we have to be familiar with the constituents of bone and what it is formed of.
Osteoporosis When we talk about osteoporosis, we have to be familiar with the constituents of bone and what it is formed of. Osteoblasts by definition are those cells present in the bone and are involved
More informationOsteoporosis - New Guidelines. Michelle Glass B.Sc. (Pharm) June 15, 2011
Osteoporosis - New Guidelines Michelle Glass B.Sc. (Pharm) June 15, 2011 Outline What is Osteoporosis? Who is at risk? What treatments are available? Role of the Pharmacy technician Definition of Osteoporosis
More informationCosting statement: Denosumab for the prevention of osteoporotic fractures in postmenopausal women
Costing statement: Denosumab for the prevention of osteoporotic fractures in postmenopausal women Resource impact The guidance Denosumab for the prevention of osteoporotic fractures in postmenopausal women
More informationControversies in Osteoporosis Management
Controversies in Osteoporosis Management 2018 Northwest Rheumatism Society Meeting Portland, OR April 28, 2018 Michael R. McClung, MD, FACP Director, Oregon Osteoporosis Center Portland, Oregon, USA Institute
More informationPage 1. Updates in Osteoporosis. I have no conflicts of interest. What is osteoporosis? What s New in Osteoporosis
Updates in Osteoporosis Jeffrey A. Tice, MD Professor of Medicine Division of General Internal Medicine, University of California, San Francisco I have no conflicts of interest What s New in Osteoporosis
More informationDownload slides:
Download slides: https://www.tinyurl.com/m67zcnn https://tinyurl.com/kazchbn OSTEOPOROSIS REVIEW AND UPDATE Boca Raton Regional Hospital Internal Medicine Conference 2017 Benjamin Wang, M.D., FRCPC Division
More informationThe management and treatment options for secondary bone disease. Omi Parikh July 2013
The management and treatment options for secondary bone disease Omi Parikh July 2013 Learning Objectives: The assessment and diagnostic process of patients with suspected bone metastases e.g bone scan,
More informationLong-term Osteoporosis Therapy What To Do After 5 Years?
Long-term Osteoporosis Therapy What To Do After 5 Years? Developing a Long-term Management Plan North American Menopause Society Philadelphia, PA October 11, 2017 Michael R. McClung, MD, FACP Institute
More informationCurrent and Emerging Strategies for Osteoporosis
Current and Emerging Strategies for Osteoporosis I have nothing to disclose. Anne Schafer, MD Assistant Professor of Medicine Division of Endocrinology & Metabolism December 12, 2014 Outline Osteoporosis
More informationOsteoporosis. Current Trend in Osteoporosis Management for Elderly in HK- Medical Perspective. Old Definition of Osteoporosis
Current Trend in Osteoporosis Management for Elderly in HK- Medical Perspective Dr Dicky T.K. Choy Physician Jockey Club Centre for Osteoporosis Care and Control, CUHK Osteoporosis Global public health
More informationClinical Policy: Denosumab (Prolia, Xgeva) Reference Number: CP.PHAR.58
Clinical Policy: (Prolia, Xgeva) Reference Number: CP.PHAR.58 Effective Date: 03/11 Last Review Date: 08/17 Coding Implications Revision Log See Important Reminder at the end of this policy for important
More informationEfficacy and Safety of Denosumab for the Treatment of Bone Metastases in Patients with Advanced Cancer
Review Articles Jpn J Clin Oncol 2012;42(8)663 669 doi:10.1093/jjco/hys088 Advance Access Publication 13 June 2012 Efficacy and Safety of Denosumab for the Treatment of Bone Metastases in Patients with
More informationCurrent Management of Metastatic Bone Disease
Current Management of Metastatic Bone Disease Evaluation and Medical Management Dr. Sara Rask Head, Medical Oncology Simcoe Muskoka Regional Cancer Centre www.rvh.on.ca Objectives 1. Outline an initial
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 15 December 2010
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 15 December 2010 DIDRONEL 200 mg, tablets B/60 (CIP code: 345 098-5) DIDRONEL 400 mg, tablets B/14 (CIP code: 333
More informationOsteoporosis: current treatment and future prospects. Juliet Compston Professor Emeritus of Bone Medicine Cambridge Biomedical Campus
Osteoporosis: current treatment and future prospects Juliet Compston Professor Emeritus of Bone Medicine Cambridge Biomedical Campus Disclosures Consultancy and speaking fees for Gilead, related to development
More informationDenosumab for the prevention of osteoporotic fractures in postmenopausal women
Denosumab for the prevention of osteoporotic fractures in Issued: October 2010 guidance.nice.org.uk/ta204 NICE has accredited the process used by the Centre for Health Technology Evaluation at NICE to
More informationCASE 1 WHY IS IT IMPORTANT TO TREAT? FACTS CONCERNS
4:30-5:15pm Ask the Expert: Osteoporosis SPEAKERS Silvina Levis, MD OSTEOPOROSIS - FACTS 1:3 older women and 1:5 older men will have a fragility fracture after age 50 After 3 years of treatment, depending
More informationBone Health in Patients with Multiple Myeloma
Bone Health in Patients with Multiple Myeloma Amrita Y. Krishnan, MD Director Judy and Bernard Briskin Myeloma Center City of Hope Comprehensive Cancer Center Bone Health Bisphosphonates in Space Bone
More informationName of Active Ingredient: Fully human monoclonal antibody to receptor activator for nuclear factor-κb ligand
Page 2 of 1765 2. SYNOPSIS Name of Sponsor: Amgen Inc. Name of Finished Product: Denosumab (AMG 162) Name of Active Ingredient: Fully human monoclonal antibody to receptor activator for nuclear factor-κb
More informationOSTEOPOROSIS: PREVENTION AND MANAGEMENT
OSTEOPOROSIS: OVERVIEW OSTEOPOROSIS: PREVENTION AND MANAGEMENT Judith Walsh, MD, MPH Departments of Medicine and Epidemiology and Biostatistics UCSF Definitions Key Risk factors Screening and Monitoring
More information1. UK List Price of Zoledronic acid (Zoledronate) 5 mg (Aclasta )
Novartis Pharmaceuticals UK Ltd Frimley Business Park Frimley Camberley Surrey GU16 7SR Dr C M Longson Director, Centre for Health Technology Evaluation National Institute for Health and Clinical Excellence
More informationOsteoporosis challenges
Osteoporosis challenges Osteoporosis challenges Who should have a fracture risk assessment? Who to treat? Drugs, holidays and unusual adverse effects Fracture liaison service? The size of the problem 1
More informationFrom Fragile to Firm. Monika Starosta MD. Advocate Medical Group
From Fragile to Firm Monika Starosta MD Advocate Medical Group Bone Remodeling 10% remodeled each year Calcium homoeostasis Maintain Mechanical strength Replace Osteocytes Release Growth Factors Bone remodeling
More informationPREVENTING BROKEN BONES:
PREVENTING BROKEN BONES: Your guide to understanding how XGEVA can help prevent broken bones and other serious bone problems* when cancer from solid tumors spreads to your bones.1 *Serious bone problems
More informationPage 1. Current and Emerging Strategies What s New in Osteoporosis. Osteoporosis. What is Osteoporosis? Traditional Risk Factors for Fracture
Current and Emerging Strategies for Osteoporosis What s New in Osteoporosis Risk stratification Douglas C. Bauer, MD University of California, San Francisco Under recognition and poor compliance New potential
More informationTreatments for Osteoporosis Expected Benefits, Potential Harms and Drug Holidays. Suzanne Morin MD FRCP FACP McGill University May 2014
Treatments for Osteoporosis Expected Benefits, Potential Harms and Drug Holidays Suzanne Morin MD FRCP FACP McGill University May 2014 Learning Objectives Overview of osteoporosis management Outline efficacy
More informationCorporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: denosumab_prolia_xgeva 3/2011 9/2017 9/2018 9/2017 Description of Procedure or Service Receptor activator
More informationDENOSUMAB SHARED CARE GUIDLINES
DENOSUMAB LICENSING Denosumab (PROLIA ) is licensed for the treatment of osteoporosis in postmenopausal women at increased risk of fractures and for bone loss associated with hormone ablation in men with
More informationPHARMACOLOGIC PROPERTIES
Denosumab Prolia TM 60mg/mL Solution for Injection PRODUCT DESCRIPTION Each pre-filled syringe contains 60 mg of denosumab in 1.0 ml solution (60 mg/ml). Clear, colourless to slightly yellow solution,
More informationOsteoporosis Clinical Guideline. Rheumatology January 2017
Osteoporosis Clinical Guideline Rheumatology January 2017 Introduction Osteoporosis is a condition of low bone mass leading to an increased risk of low trauma fractures. The prevalence of osteoporosis
More informationCastrate-resistant prostate cancer: Bone-targeted agents. Pr Karim Fizazi, MD, PhD Institut Gustave Roussy Villejuif, France
Castrate-resistant prostate cancer: Bone-targeted agents Pr Karim Fizazi, MD, PhD Institut Gustave Roussy Villejuif, France Disclosure Participation in advisory boards or as a speaker for: Amgen, Astellas,
More informationName of Policy: Zoledronic Acid (Reclast ) Injection
Name of Policy: Zoledronic Acid (Reclast ) Injection Policy #: 355 Latest Review Date: May 2011 Category: Pharmacy Policy Grade: Active Policy but no longer scheduled for regular literature reviews and
More informationManagement of postmenopausal osteoporosis
Management of postmenopausal osteoporosis Yeap SS, Hew FL, Chan SP, on behalf of the Malaysian Osteoporosis Society Committee Working Group for the Clinical Guidance on the Management of Osteoporosis,
More informationGuideline for the investigation and management of osteoporosis. for hospitals and General Practice
Guideline for the investigation and management of osteoporosis for hospitals and General Practice Background Low bone density is an important risk factor for fracture. The aim of assessing bone density
More informationPROLIA: Medical Coverage Policy Denosumab (Prolia and. Xgeva) EFFECTIVE DATE: POLICY LAST UPDATED:
Medical Coverage Policy Denosumab (Prolia and Xgeva) EFFECTIVE DATE: 11 01 2016 POLICY LAST UPDATED: 12 19 2017 OVERVIEW Prolia (denosumab) is indicated for the treatment of postmenopausal women with osteoporosis
More informationOsteoporosis: A Tale of 3 Task Forces!
Osteoporosis: A Tale of 3 Task Forces! Robert A. Adler, MD McGuire Veterans Affairs Medical Center Virginia Commonwealth University Richmond, Virginia, USA Disclosures The opinions are those of the speaker
More informationOsteoporosis: An Overview. Carolyn J. Crandall, MD, MS
Osteoporosis: An Overview Carolyn J. Crandall, MD, MS Osteoporosis: An Overview Carolyn J. Crandall, MD, MS Professor of Medicine David Geffen School of Medicine at UCLA Objectives Review osteoporosis
More informationJohn J. Wolf, DO Family Medicine
John J. Wolf, DO Family Medicine Objectives: 1. Review incidence & Risk of Osteoporosis 2.Review indications for testing 3.Review current pharmacologic & Non pharmacologic Tx options 4.Understand & Utilize
More informationKristen M. Nebel, DO PENN/ LGHP Geriatrics. Temple Family Medicine Review
Kristen M. Nebel, DO PENN/ LGHP Geriatrics 10/3/17 Temple Family Medicine Review OBJECTIVES Define Revised 2017 American College of Physician Recommendations Screening, Prevention and Treatment Application
More informationThe Latest is the Greatest. Future Directions in the Management of Patients with Bone Metastases from Breast Cancer
City Wide Medical Oncology Rounds Friday Sept. 21 st, 2007 The Latest is the Greatest Future Directions in the Management of Patients with Bone Metastases from Breast Cancer Mark Clemons Head, Breast Medical
More informationCigna Drug and Biologic Coverage Policy
Cigna Drug and Biologic Coverage Policy Subject Denosumab Table of Contents Coverage Policy... 1 General Background... 4 Coding/Billing Information... 9 References... 9 Effective Date... 7/1/2018 Next
More informationDenosumab for the prevention of osteoporotic fractures in postmenopausal women
Issue date: October 2010 Denosumab for the prevention of osteoporotic fractures in postmenopausal women This guidance was developed using the single technology appraisal process NICE technology appraisal
More informationName of Policy: Boniva (Ibandronate Sodium) Infusion
Name of Policy: Boniva (Ibandronate Sodium) Infusion Policy #: 266 Latest Review Date: April 2010 Category: Pharmacology Policy Grade: Active Policy but no longer scheduled for regular literature reviews
More informationOverview. Bone Biology Osteoporosis Osteomalacia Paget s Disease Cases. People Centred Positive Compassion Excellence
Overview Osteoporosis and Metabolic Bone Disease Dr Chandini Rao Consultant Rheumatologist Bone Biology Osteoporosis Osteomalacia Paget s Disease Cases Bone Biology Osteoporosis Increased bone remodelling
More informationOsteoporosis: Are your bones at risk of fracturing? Rachel Wallwork, MD Internal medicine resident Massachusetts General Hospital
Osteoporosis: Are your bones at risk of fracturing? Rachel Wallwork, MD Internal medicine resident Massachusetts General Hospital What is Osteoporosis? Osteoporosis causes bones to lose density, become
More informationPrior Authorization Required: Yes as shown below
PROLIA, XGEVA (denosumab) MB9409 Covered Service: Prior Authorization Required: Additional Information Medicare Policy: BadgerCare Plus Policy: Yes when meets criteria below Yes as shown below Must be
More informationCurrent Issues in Osteoporosis
Current Issues in Osteoporosis California AACE 18TH Annual Meeting & Symposium Marina del Rey, CA September 15, 2018 Michael R. McClung, MD, FACP,FACE Director, Oregon Osteoporosis Center Portland, Oregon,
More informationOsteoporosis/Fracture Prevention
Osteoporosis/Fracture Prevention NATIONAL GUIDELINE SUMMARY This guideline was developed using an evidence-based methodology by the KP National Osteoporosis/Fracture Prevention Guideline Development Team
More informationQuestions and Answers About Breast Cancer, Bone Metastases, & Treatment-Related Bone Loss. A Publication of The Bone and Cancer Foundation
Questions and Answers About Breast Cancer, Bone Metastases, & Treatment-Related Bone Loss A Publication of The Bone and Cancer Foundation Contents This publication includes important information about
More informationSpongeBone Menopants*
SpongeBone Menopants* Adam Fershko, MD, FACP Kettering Health Network *Postmenopausal Osteoporosis Objectives O Epidemiology O Clinical significance O Pathophysiology O Screening and Diagnosis O Treatment
More informationGreater Manchester Interface Prescribing Group Shared Care Template
Greater Manchester Interface Prescribing Group Shared Care Template Shared Care Guideline the use of Denosumab for the prevention of osteoporotic fractures in postmenopausal women. Author(s)/Originator(s):
More informationCurrent and Emerging Approaches for Osteoporosis
Current and Emerging Approaches for Osteoporosis Douglas C. Bauer, MD Professor of Medicine and Epidemiology & Biostatistics University of California, San Francisco No Disclosures What s New in Osteoporosis
More information